The business consists of a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, VMS, dermatology, pain and vaccines
Dr Reddy’s Laboratories entered into a definitive agreement with Wockhardt to acquire select divisions of its branded generics business in India and a few other international territories, including Sri Lanka and the Maldives for Rs 1850 crores, the drugmaker said. The business consists of a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, VMS, dermatology, pain and vaccines, which would transfer to Dr Reddy’s along with related sales and marketing teams and the manufacturing plant located in Baddi, Himachal Pradesh with all plant employees, a release said. The business undertaking is being transferred on an outright sale basis.
GV Prasad, Co-Chairman and MD, Dr Reddy’s, said, “India is an important market for us and this acquisition will help in considerably scaling-up our domestic business.” “The acquired portfolio shall enhance Dr Reddy’s presence in the high growth therapy areas with market-leading brands such as Practin, Zedex, Bro-zedex, Tryptomer and Biovac. We believe the portfolio holds a lot of potentials and will get an impetus under Dr Reddy’s. We welcome the team joining as part of the deal to Dr Reddy’s family.”
The transaction is expected to be closed in the first quarter of the financial year 2020-21.